New Self-Amplifying mRNA vaccine aims to better protect transplant patients against COVID-19
NCT ID NCT07390968
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new COVID-19 vaccine (LUNAR-COV19) in 56 adults who received a blood stem cell transplant within the past year. These patients often have weaker immune responses to standard vaccines. The new vaccine uses a self-amplifying mRNA that may produce a stronger and longer-lasting immune response. Researchers will compare it to the standard Pfizer vaccine to see which is safer and more effective.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEMATOPOIETIC AND LYMPHATIC SYSTEM NEOPLASM are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Fred Hutch/University of Washington Cancer Consortium
Seattle, Washington, 98109, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A virtual pharmacy visit may ease opioid fears for cancer patients
- Can meditation tame the Long-Term side effects of a stem cell transplant?
- Strumming through treatment: can ukulele lessons shield teen brains from Radiation's toll?
- A smartphone app may help young cancer survivors get fitter — a trial puts it to the test
- Faith and mindfulness join forces to heal black cancer survivors
- Sniffing away sickness: essential oils tested for chemo nausea